REVB on Nasdaq
REVELATION BIOSCIENCES, INC.
American pharmaceutical preparations company based in San Diego.
Price unavailable
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $4.1M | $3.5M |
| General and administrative | $5.0M | $4.4M |
| Total operating expenses | $9.1M | $8.0M |
| Loss from operations | -$9.1M | -$8.0M |
| Change in fair value of warrant liability | $2.2K | $81.4K |
| Other income (expense), net | $155.0K | -$7.1M |
| Total other income (expense), net | $157.2K | -$7.1M |
| Net loss | -$8.9M | -$15.0M |
| Deemed dividends | -$6.0M | |
| Net loss attributable to common stockholders | -$14.9M | -$15.0M |
| Net loss per share, basic | -$23.95 | -$1,052.16 |
| Net loss per share, diluted | -$23.95 | -$1,052.16 |
| Weighted-average shares used to compute net loss per share, basic | 620.8K shares | 14.3K shares |
| Weighted-average shares used to compute net loss per share, diluted | 620.8K shares | 14.3K shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $10.7M | $6.5M | |
| Prepaid expenses and other current assets | $111.3K | $66.7K | |
| Total current assets | $10.8M | $6.6M | |
| Property and equipment, net | $18.1K | $56.3K | |
| Operating lease right-of-use asset | $722.3K | $0 | |
| Other assets | $30.9K | $0 | |
| Total assets | $11.6M | $6.6M | |
| Accounts payable | $577.5K | $783.6K | |
| Accrued expenses | $1.4M | $1.1M | |
| Operating lease liability | $23.0K | $0 | |
| Total current liabilities | $2.0M | $1.9M | |
| Operating lease liability, net of current portion | $723.8K | $0 | |
| Total liabilities | $2.7M | $1.9M | |
| Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024 and 1,583,969 and 43,526 issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $1.6K | $44 | |
| Additional paid-in-capital | $58.3M | $45.2M | |
| Accumulated deficit | -$49.4M | -$40.5M | |
| Total stockholders' equity | $8.9M | $4.7M | $6.6M |
| Total liabilities and stockholders' equity | $11.6M | $6.6M | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | |
| Common stock, shares issued | 1.6M shares | 43.5K shares | |
| Common stock, shares outstanding | 1.6M shares | 43.5K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $10.7M | $6.5M | |
| Prepaid expenses and other current assets | $111.3K | $66.7K | |
| Total current assets | $10.8M | $6.6M | |
| Property and equipment, net | $18.1K | $56.3K | |
| Operating lease right-of-use asset | $722.3K | $0 | |
| Other assets | $30.9K | $0 | |
| Total assets | $11.6M | $6.6M | |
| Accounts payable | $577.5K | $783.6K | |
| Accrued expenses | $1.4M | $1.1M | |
| Operating lease liability | $23.0K | $0 | |
| Total current liabilities | $2.0M | $1.9M | |
| Operating lease liability, net of current portion | $723.8K | $0 | |
| Total liabilities | $2.7M | $1.9M | |
| Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024 and 1,583,969 and 43,526 issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $1.6K | $44 | |
| Additional paid-in-capital | $58.3M | $45.2M | |
| Accumulated deficit | -$49.4M | -$40.5M | |
| Total stockholders' equity | $8.9M | $4.7M | $6.6M |
| Total liabilities and stockholders' equity | $11.6M | $6.6M | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | |
| Common stock, shares issued | 1.6M shares | 43.5K shares | |
| Common stock, shares outstanding | 1.6M shares | 43.5K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$8.9M | -$15.0M |
| Stock-based compensation expense | $595.4K | $168.8K |
| Depreciation expense | $27.1K | $27.9K |
| Non-cash lease expense | $18.6K | |
| Loss on disposal of equipment | $11.2K | |
| Change in fair value of warrant liability | -$2.2K | -$81.4K |
| Issuance of common stock for services | $25.0K | |
| Prepaid expenses and other current assets | -$44.6K | $18.0K |
| Deferred offering costs | $71.1K | |
| Other assets | -$30.9K | |
| Accounts payable | -$206.1K | -$576.3K |
| Accrued expenses | $269.8K | -$2.9M |
| Operating lease liability | $5.9K | |
| Net cash used in operating activities | -$8.3M | -$18.3M |
| Purchase of property and equipment | -$19.2K | |
| Net cash used in investing activities | -$19.2K | |
| Net cash provided by financing activities | $12.5M | $12.8M |
| Net increase (decrease) in cash and cash equivalents | $4.2M | -$5.5M |
| Deemed dividend for exercise price reductions of warrants | $6.0M | |
| Operating lease right-of-use asset exchanged for lease liability | $740.9K |
No quarter-by-quarter statement was filed.
Leadership
Who has led REVELATION BIOSCIENCES, INC., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
2025
- Chief executive officerJames Rolke Jan 20, 2022 to now12
- Chief executive officerAndreas Typaldos Oct 21, 2020 to Dec 31, 202013
- Chief executive officerSean H. Fitzpatrick Dec 31, 2020 to Dec 31, 202014
- Chief financial officerChester Stanley Zygmont Iii. Jan 20, 2022 to now15
- Chief financial officerSean H. Fitzpatrick Oct 13, 2020 to Oct 20, 202016
Board members and other officers (13)
- Board memberLakhmir S. Chawla Oct 2, 2023 to now17
- Board memberCurt H. Labelle Jan 20, 2022 to Apr 18, 202318
- Board memberGeorge F. Tidmarsh Jan 20, 2022 to Feb 13, 202519
- Board memberJames Rolke Jan 20, 2022 to now12
- Board memberJennifer Carver Jan 20, 2022 to now20
- Board memberJess Roper Jan 20, 2022 to now21
- Board memberAnthony Hayes Oct 9, 2020 to Oct 9, 202022
- Board memberBarry Dennis Oct 9, 2020 to Oct 9, 202023
- Board memberDavid Dobkin Oct 9, 2020 to Oct 9, 202024
- Board memberKimon Angelides Oct 9, 2020 to Oct 9, 202025
- Board memberRobert D. Nicholson Oct 9, 2020 to Oct 9, 202026
- Board memberSean H. Fitzpatrick Oct 13, 2020 to Dec 31, 202016
- Board memberAndreas Typaldos Oct 21, 2020 to Dec 31, 202013
Former names
- Petra Acquisition Inc.May 14, 2020 to Jan 11, 20222
Timeline
Filings
327 filings to the SEC since October 2021: 6 annual reports, 17 quarterly reports, 89 major events, 54 insider forms, 27 large holders, 134 other. The latest 20:
- Aug 19, 20268-K EDGAR
- Aug 18, 20264 EDGAR
- Aug 18, 20264 EDGAR
- Aug 18, 20264 EDGAR
- Aug 18, 20264 EDGAR
- Aug 18, 20264 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 6, 20268-K EDGAR
- Aug 6, 202610-Q EDGAR
- Jul 13, 20268-A12B EDGAR
- Jul 13, 20268-K EDGAR
- Jun 24, 20268-K EDGAR
- Jun 1, 20268-K EDGAR
- May 15, 2026SCHEDULE 13G EDGAR
- May 11, 2026ARS EDGAR
- May 11, 2026DEF 14A EDGAR
- May 7, 20268-K EDGAR
- May 7, 202610-Q EDGAR
- May 1, 20264 EDGAR
- May 1, 20264 EDGAR
The 327 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 27 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G
- Feb 17, 2026SCHEDULE 13G/A
- Jan 20, 2026SCHEDULE 13G
- Nov 14, 2025SCHEDULE 13G
- Jan 2, 2025SCHEDULE 13G/A
- Feb 13, 2024SC 13G/A
- Feb 12, 2024SCHEDULE 13G/A
- Jan 3, 2024SC 13G
- Feb 21, 2023SC 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Sabby Management, LLC | 210,582 | $216.9K | 1.8% | +111,150 |
| Citadel Advisors LLC | 38,579 | $39.7K | 0.0% | New |
| Geode Capital Management, LLC | 17,192 | $17.7K | 0.0% | −26,003 |
| Vanguard Fiduciary Trust Co | 13,127 | $13.5K | 0.0% | No change |
| Tower Research Capital LLC (TRC) | 6,528 | $6.7K | 0.0% | +2,454 |
| Royal Bank Of Canada | 747 | $1.0K | 0.0% | No change |
| SBI Securities Co., Ltd. | 344 | $354 | 0.0% | No change |
| Barclays PLC | 168 | $173 | 0.0% | New |
| Hrt Financial LP | 16,978 | $17 | 0.0% | New |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 9 | $9 | 0.0% | No change |
| Caitong International Asset Management Co., Ltd | 1 | $1 | 0.0% | No change |
| Fmr LLC | 0 | $0 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARJames Rolke, Chief executive officer
- 13
- 14
- 15
- 16
- 17SEC EDGARLakhmir S. Chawla, Board member
- 18SEC EDGARCurt H. Labelle, Board member
- 19SEC EDGARGeorge F. Tidmarsh, Board member
- 20SEC EDGARJennifer Carver, Board member
- 21SEC EDGARJess Roper, Board member
- 22SEC EDGARAnthony Hayes, Board member
- 23SEC EDGARBarry Dennis, Board member
- 24SEC EDGARDavid Dobkin, Board member
- 25SEC EDGARKimon Angelides, Board member
- 26SEC EDGARRobert D. Nicholson, Board member
- 27